

CITATION REPORT

List of articles citing

Clinical development of CT-P6 in HER2 positive breast cancer

DOI: 10.1080/14712598.2019.1665019

Expert Opinion on Biological Therapy, 2019, 19, 987-992.

Source: <https://exaly.com/paper-pdf/72723547/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 689587	5.3	3
1	Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. 2022 , 10, 2045		0